Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial

Patrice Forget* (Corresponding Author), Martine Berlière, Aline van Maanen, Francois P. Duhoux, Jean-Pascal Machiels, Pierre G. Coulie, Gauthier Bouche, Marc De Kock, Ketorolac in Breast Cancer trial (KBCtrial) group

*Corresponding author for this work

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).
Original languageEnglish
Pages (from-to)707-712
Number of pages6
JournalMedical Hypotheses
Volume81
Issue number4
Early online date9 Aug 2013
DOIs
Publication statusPublished - Oct 2013

Fingerprint Dive into the research topics of 'Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Forget, P., Berlière, M., van Maanen, A., Duhoux, F. P., Machiels, J-P., Coulie, P. G., Bouche, G., De Kock, M., & Ketorolac in Breast Cancer trial (KBCtrial) group (2013). Perioperative ketorolac in high risk breast cancer patients: Rationale, feasibility and methodology of a prospective randomized placebo-controlled trial. Medical Hypotheses, 81(4), 707-712. https://doi.org/10.1016/j.mehy.2013.07.033